Revenue Breakdown
Composition ()
No data
Revenue Streams
Emergent BioSolutions Inc (EBS) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Commercial Product sales, accounting for 47.9% of total sales, equivalent to $67.50M. Other significant revenue streams include MCM Product sales and Contracts and grants. Understanding this composition is critical for investors evaluating how EBS navigates market cycles within the Pharmaceuticals industry.
Profitability & Margins
Evaluating the bottom line, Emergent BioSolutions Inc maintains a gross margin of 42.70%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -10.76%, while the net margin is -36.72%. These profitability ratios, combined with a Return on Equity (ROE) of 10.46%, provide a clear picture of how effectively EBS converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, EBS competes directly with industry leaders such as IMMX and KROS. With a market capitalization of $421.93M, it holds a significant position in the sector. When comparing efficiency, EBS's gross margin of 42.70% stands against IMMX's N/A and KROS's 100.00%. Such benchmarking helps identify whether Emergent BioSolutions Inc is trading at a premium or discount relative to its financial performance.
